Cargando…

Immune‐mediated thrombotic thrombocytopenic purpura in a Jehovah’s Witness – Effectiveness of incorporating extracorporeal immunoadsorption to caplacizumab, steroids and rituximab

We report the case of a Jehovah's Witness adolescent patient with immune‐mediated thrombotic thrombocytopenic purpura after SARS‐Cov2 infection successfully treated without therapeutic plasma exchange (TPE) using caplacizumab, corticosteroids, rituximab, and extracorporeal immunoadsorption (EIA...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cardesa‐Salzmann, Teresa Marta, Stephan, Bernhard, Simon, Arne, Furtwängler, Rhoikos, Schöndorf, Dominik, Heine, Sabine, Torfah, Eyad, Lux, Margaux, Meyer, Sonja, Graf, Norbert
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Case Reports
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9122792/ https://www.ncbi.nlm.nih.gov/pubmed/35600013 http://dx.doi.org/10.1002/ccr3.5902

Ejemplares similares

Thrombotic thrombocytopenic purpura treated with vincristine in a Jehovah's witness
por: Walia, Sandeep S., et al.
Publicado: (2011)

Caplacizumab for thrombotic thrombocytopenic purpura
Publicado: (2020)

Caplacizumab for Acute Thrombotic Thrombocytopenic Purpura
por: Katsivalis, Katherine V., et al.
Publicado: (2021)

Caplacizumab use for immune thrombotic thrombocytopenic purpura: the Milan thrombotic thrombocytopenic purpura registry
por: Agosti, Pasquale, et al.
Publicado: (2023)

Caplacizumab in adult patients with acquired thrombotic thrombocytopenic purpura
por: Hanlon, Ashley, et al.
Publicado: (2020)

Shared decision making, thrombotic thrombocytopenic purpura, and caplacizumab
por: Sukumar, Senthil, et al.
Publicado: (2020)

Successful Management of Thrombotic Thrombocytopenic Purpura in a Jehovah’s Witness: An Individualized Approach With Joint Decision-Making
por: Lim, Ming Y, et al.
Publicado: (2019)

Caplacizumab as an emerging treatment option for acquired thrombotic thrombocytopenic purpura
por: Elverdi, Tugrul, et al.
Publicado: (2019)

Clinical Efficacy and Safety Profile of Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura
por: Maqsood, Muhammad Haisum, et al.
Publicado: (2019)

How should caplacizumab be used for treatment of immune thrombotic thrombocytopenic purpura?
por: Zheng, Lucy, et al.
Publicado: (2023)

Caplacizumab for immune thrombotic thrombocytopenic purpura: real-world multicenter data
por: Gavriilaki, Eleni, et al.
Publicado: (2023)

More on the use of frontline caplacizumab in immune-mediated thrombotic thrombocytopenic purpura
por: Picod, Adrien, et al.
Publicado: (2022)

Delayed Thrombotic Complications in a Thrombotic Thrombocytopenic Purpura Patient Treated With Caplacizumab
por: Cilla, Nicolas, et al.
Publicado: (2020)

Outcomes in 1096 patients with severe thrombotic thrombocytopenic purpura before the Caplacizumab era
por: Van de Louw, Andry, et al.
Publicado: (2021)

Prolonged Exposure to Caplacizumab as Rescue Therapy in Refractory Immune Thrombotic Thrombocytopenic Purpura
por: Rodgers, George M, et al.
Publicado: (2023)

Safe and Effective Administration of Caplacizumab in COVID-19-Associated Thrombotic Thrombocytopenic Purpura
por: Bruzzese, Antonella, et al.
Publicado: (2023)

Post Approval Experience with Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura at a Single Institution
por: Logothetis, Constantine N., et al.
Publicado: (2021)

Caplacizumab Model‐Based Dosing Recommendations in Pediatric Patients With Acquired Thrombotic Thrombocytopenic Purpura
por: Bergstrand, Martin, et al.
Publicado: (2021)

Real-world effectiveness of caplacizumab vs the standard of care in immune thrombotic thrombocytopenic purpura
por: Izquierdo, Cristina Pascual, et al.
Publicado: (2022)

Brazilian experience with caplacizumab in acquired thrombotic thrombocytopenic purpura: outcomes of the expanded access program
por: de Oliveira Boechat, Tiago, et al.
Publicado: (2023)

Successful Treatment of Refractory Thrombotic Thrombocytopenic Purpura (TTP) With Caplacizumab: A Case Report
por: Pramanik, Debolina, et al.
Publicado: (2023)

Treatment of acquired thrombotic thrombocytopenic purpura without plasma exchange in selected patients under caplacizumab
por: Völker, Linus A., et al.
Publicado: (2020)

Adding caplacizumab to standard of care in thrombotic thrombocytopenic purpura: a systematic review and meta-analysis
por: Djulbegovic, Mia, et al.
Publicado: (2022)

Anesthetic management of Jehovah's Witness patients.
por: Kim, W. O.
Publicado: (1991)

Surgery in Jehovah's Witnesses – our experience
por: Trzciński, Radzisław, et al.
Publicado: (2015)

Evans Syndrome in a Jehovah’s Witness
por: Leonhardt, Lex P, et al.
Publicado: (2021)

Efficacy and safety of open‐label caplacizumab in patients with exacerbations of acquired thrombotic thrombocytopenic purpura in the HERCULES study
por: Knoebl, Paul, et al.
Publicado: (2019)

Vemurafenib as bridging therapy of hairy cell leukemia in a Jehovah’s Witness patient
por: Schlaweck, Sebastian, et al.
Publicado: (2021)

P1608: REAL-WORLD INSIGHTS ON THE MANAGEMENT OF IMMUNE-MEDIATED THROMBOTIC THROMBOCYTOPENIC PURPURA (ITTP) WITH CAPLACIZUMAB IN BELGIUM
por: Dierickx, Daan, et al.
Publicado: (2023)

A Rare Case of Severe Manifestation of COVID-19 Infection Presenting as Immune-Related Thrombotic Thrombocytopenic Purpura With Multiorgan Involvement Treated With Plasmapheresis, Steroids, Rituximab, and Caplacizumab
por: Mandyam, Saikiran, et al.
Publicado: (2022)

Successful transfusion-free pancreatectomy in Jehovah's Witness patients
por: Lee, Jong Oh, et al.
Publicado: (2016)

Blood Transfusion in Children: The Refusal of Jehovah’s Witness Parents’
por: Conti, Adelaide, et al.
Publicado: (2018)

52-Year-Old Jehovah’s Witness Female with Weakness
por: Weiner, Lindsay A., et al.
Publicado: (2018)

Liver transplantation in Jehovah's Witnesses: two cases report
por: Jeong, Ju-Young, et al.
Publicado: (2017)

Ceftriaxone-Induced Hemolytic Anemia in a Jehovah’s Witness
por: Tasch, James, et al.
Publicado: (2017)

Jehovah’s Witnesses and Their Compliance with Regulations on Smoking and Blood Treatment
por: Pavlikova, Barbara, et al.
Publicado: (2021)

Grieving the Living: The Social Death of Former Jehovah’s Witnesses
por: Ransom, Heather J., et al.
Publicado: (2021)

Unmet needs in the management of immune‐mediated thrombotic thrombocytopenic purpura and the potential role of caplacizumab in the UK—A modified‐Delphi study
por: Scully, Marie, et al.
Publicado: (2022)

The efficacy and safety of caplacizumab in Japanese patients with immune-mediated thrombotic thrombocytopenic purpura: an open-label phase 2/3 study
por: Miyakawa, Yoshitaka, et al.
Publicado: (2022)

Treatment of Jehovah’s witness patients. Surgical and medico-legal considerations
por: Terranova, C, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_1n1h63mqqop8329pbhe6550nlr